EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 34 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French MOST POPULAR Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October October 14, 2024 Should CAR T Cells Be Used Earlier in People with Non-Hodgkin... January 13, 2022 Καρκίνος οισοφάγου January 22, 2019 Study in India Could Make Immunotherapy More Affordable Worldwide November 22, 2022 Load more HOT NEWS Spending Review 2020 – Steps in the right direction, but opportunities... FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic... Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Young Women At Increased Risk Of Aggressive Breast Cancer
